Durvalumab with or without Olaparib as Maintenance Therapy after First-Line Treatment of Advanced and Recurrent Endometrial Cancer - DUO-E

Inclusion Criteria

• - Age ≥18 years at the time of screening and female.
• - Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies, including carcinosarcomas, will be allowed. Sarcomas will not be allowed.
• - Patient must have endometrial cancer in one of the following categories:
• a) Newly diagnosed Stage III disease (measurable disease per RECIST 1.1 following surgery or diagnostic biopsy),
• b) Newly diagnosed Stage IV disease (with or without disease following surgery or diagnostic biopsy)
• c) Recurrence of disease (measurable or non-measurable disease per RECIST 1.1) where the potential for cure by surgery alone or in combination is poor.
• - Naïve to first line systemic anti-cancer treatment. For patients with recurrent disease only, prior systemic anti-cancer treatment is allowed only if it was administered in the adjuvant setting and there is at least 12 months from date of last dose of systemic anti-cancer treatment administered to date of subsequent relapse
• - FPPE tumor sample must be available for MMR evaluation.
• - Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days of starting study treatment.